tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NMRA Stock Latest News

Neumora outlines 2026 neuroscience pipeline and obesity plans
Company AnnouncementsNeumora outlines 2026 neuroscience pipeline and obesity plans
3d ago
8K
NMRA
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
PremiumRatings
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
3d ago
NMRA
Neumora Therapeutics initiated with an Outperform at Leerink
PremiumThe Fly
Neumora Therapeutics initiated with an Outperform at Leerink
3d ago
NMRA
Neumora Therapeutics price target raised to $6 from $5 at Mizuho
PremiumThe Fly
Neumora Therapeutics price target raised to $6 from $5 at Mizuho
9d ago
NMRA
Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
PremiumRatings
Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
10d ago
NMRA
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
PremiumRatingsPositive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
10d ago
NMRA
Neumora reports promising Phase 1b results in Alzheimer’s agitation
Premium
Company Announcements
Neumora reports promising Phase 1b results in Alzheimer’s agitation
10d ago
8K
NMRA
Neumora Therapeutics announces results from NMRA-511 Phase 1b study
Premium
The Fly
Neumora Therapeutics announces results from NMRA-511 Phase 1b study
10d ago
NMRA
Neumora Therapeutics highlights 2026 pipeline strategy
PremiumThe Fly
Neumora Therapeutics highlights 2026 pipeline strategy
10d ago
NMRA
Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
PremiumThe Fly
Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
1M ago
B
BX
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
PremiumThe Fly
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
2M ago
NMRA
Neumora Issues Shares Following Loan Conversion Notice
PremiumCompany Announcements
Neumora Issues Shares Following Loan Conversion Notice
2M ago
8K
NMRA
Neumora Therapeutics price target raised to $3 from $2 at Stifel
PremiumThe FlyNeumora Therapeutics price target raised to $3 from $2 at Stifel
2M ago
NMRA
LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
Premium
The Fly
LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
2M ago
LBRX
NMRA
Neumora Therapeutics Reports Q3 2025 Progress and Financials
Premium
Company Announcements
Neumora Therapeutics Reports Q3 2025 Progress and Financials
2M ago
NMRA
Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment
PremiumRatings
Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment
2M ago
NMRA
Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)
PremiumThe Fly
Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)
2M ago
NMRA
Neumora Therapeutics price target raised to $8 from $6 at Needham
PremiumThe Fly
Neumora Therapeutics price target raised to $8 from $6 at Needham
3M ago
NMRA
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
PremiumCompany Announcements
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
3M ago
NMRA
Neumora Therapeutics Advances MDD Treatment with Long-term Study
PremiumCompany AnnouncementsNeumora Therapeutics Advances MDD Treatment with Long-term Study
3M ago
NMRA
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder
Premium
Company Announcements
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder
3M ago
NMRA
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment
Premium
Company Announcements
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment
3M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >